ANIK
ANIK
NASDAQ · Biotechnology

Anika Therapeutics Inc

$14.98
+0.48 (+3.31%)
As of Apr 1, 10:08 PM ET ·
Financial Highlights (FY 2026)
Revenue
105.44M
Net Income
-10,168,490
Gross Margin
56.6%
Profit Margin
-9.6%
Rev Growth
-10.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 56.6% 56.6% 28.3% 28.3%
Operating Margin -9.8% -8.8% 27.9% 28.4%
Profit Margin -9.6% -9.2% 22.9% 26.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 105.44M 117.52M 23.45M 26.68M
Gross Profit 59.64M 66.47M 6.64M 7.56M
Operating Income -10,332,836 -10,365,082 6.55M 7.58M
Net Income -10,168,490 -10,200,224 5.38M 7.18M
Gross Margin 56.6% 56.6% 28.3% 28.3%
Operating Margin -9.8% -8.8% 27.9% 28.4%
Profit Margin -9.6% -9.2% 22.9% 26.9%
Rev Growth -10.3% -10.3% -4.1% +21.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 38.69M 41.86M
Total Equity 99.18M 96.99M
D/E Ratio 0.39 0.43
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -5,308,037 -5,620,413 8.65M 11.22M
Free Cash Flow 4.59M 6.09M